OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its breakthrough ultrasound-based drug delivery platform,
reports that the first patient had been dosed in the treatment cohorts of its first-in-human clinical investigation (ISRCTN17598292) on May 23, 2023. This is the first patient to receive chemotherapy drugs in addition to SonoTran® and was completed without issues as well as recruited in Cohort 3 of the clinical study. Many patients are under screening for recruitment in both Cohort 2 & 3 on an ongoing basis.

This follows successful completion of cohort 1 evaluating the tolerability of SonoTran® at each of three different doses of Particles (nine patients in total) as well as SonoTran Particle cavitation at each dose level using the company’s proprietary “see as you treat” passive acoustic mapping technology. SonoTran® is being evaluated in a phase I/IIa multicenter clinical investigation in patients with metastatic colorectal cancer (mCRC) funded by the National Institute for Health Research (NIHR).

The clinical investigation now includes two patient treatment cohorts to evaluate:
Cohort 2. SonoTran®’s ability to enhance the delivery of cetuximab and irinotecan into tumors in resectable mCRC patients; and
Cohort 3. SonoTran®’s ability to enhance tumor response to standard of care first-line chemotherapy (cetuximab + FOLFIRI) in unresectable mCRC patients.

Cohorts 2 and 3 are currently recruiting patients at the Oxford Cancer Centre, Churchill Hospital,

Oxford University Hospitals (OUH) NHS Foundation Trust. Cohort 2 is additionally recruiting patients at the Queen Elizabeth Hospital, Birmingham (UHB) NHS Foundation Trust. The coordinating investigator of the whole trial and the OUH site Principal Investigator is Professor Rachel Kerr (Department of Oncology, University of Oxford).

Jérôme Marzinski, CEO commented: “We’re delighted that the investigation of SonoTran® is continuing to treatment phase and that we can show the technology is, as predicted by the wealth of preclinical evidence, able to deliver more anti-cancer therapy into and through the tumor. This is a significant milestone achieved by OxSonics that creates a new positive momentum aiming to bring compelling comparative effectiveness of SonoTran® for solid tumor treatment.”

About CEeDD Clinical Study
SonoTran® is being evaluated in a phase I/IIa multicenter clinical investigation in patients with metastatic colorectal cancer (mCRC) funded by the National Institute for Health Research (NIHR).